ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO248

Mortality of Patients with Cancer and AKI: What Are the Lessons?

Session Information

Category: Onconephrology

  • 1700 Onconephrology


  • Oliveira, Alline, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Valenca, Andrea C.E.P, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Nascimento, Joseph Lopes, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Lacerda, Thiago Martins, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Feijo de Melo, Klebson Fellipe, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Alves, Italo Rafael Correia, Hospital das Clinicas, Recife, Pernambuco, Brazil
  • Gueiros, Ana Paula, Hospital das Clinicas, Recife, Pernambuco, Brazil

Acute kidney injury (AKI) is a prevalent complication in cancer patients, contributing to mortality. This study aimed to assess factors associated with the mortality of patients with cancer and AKI monitored in the onconephrology clinic of a university hospital.


This was a cross-sectional, retrospective study. Medical records were reviewed of patients monitored from January 2018 to December 2022. Patients with COVID-19 were excluded. AKI was defined according to KDIGO criteria. The final creatinine (CrF mg/dL): last value measured before discharge or death; oliguria: diuresis <400 mL/24h. A comparative analysis was performed of patients who died and survivors. Univariate and multivariate analyzes were used in the search for risk factors for death. The impact was assessed of hyperphosphatemia (phosphorus>4.5mg/dL) and hyponatremia (sodium<135mEq/L) on mortality.


A total of 340 patients (50% male), with a median age of 62 years, were studied. The mean follow-up time was 15 days. Most patients (78%) presented solid tumors. Types of AKI were: intrinsic renal (38%), prerenal (30%), and obstructive (27%). Outcome data were available on 336 patients. One hundred and eighteen patients (35%) died. Patients who died differed from survivors by being in ICU (55% x 17%; p<0.001), intrinsic renal AKI (57% x 27%; p<0.001), sepsis (58% x 19%; p<0.001), urine output (mL) (500 x 1050; p<0.001), need for renal replacement therapy (RRT) (60% x 25%; p<0.001), CrF (3.2 x 1.5; p<0.001), phosphorus (4.6 x 4.0; p=0.018) and albumin (g/dL) (2.8 X 3.0; p=0.046). In the univariate analysis, the following were associated with mortality: not being in ICU (OR 0.17; p<0.001), CrF (OR 2.26; p<0.001), intrinsic renal AKI (OR 3.47; p<0.001), no sepsis (OR 0.17; p<0.001), non- oliguric (OR 0.31; p<0.001), phosphorus (OR 1.2; p=0.023) and no need for RRT (OR 0.22; p<0.001). In the multivariate analysis, only CrF was an independent risk factor for death (OR 7.51; p=0.009). Hyperphosphatemia was associated with mortality (p=0.006), but hyponatremia was not (p=0.8).


We confirmed the high mortality rate of patients with cancer and AKI. The severity and persistence of AKI are determinants of mortality.
Hyperphosphatemia seems to be a predictor of mortality in cancer patients with AKI.